LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the fourth quarter and year ended December 31, 2014 and provided an operational update.
“This past year has been marked by both significant progress and change for the organization. With new leadership and a renewed focus, we are laying the foundation for building a leading oncology biopharmaceutical company and realizing the value of our lead clinical candidate, ganetespib, and our proprietary Hsp90 inhibitor Drug Conjugate program,” said Anne Whitaker, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
“This past year has been marked by both significant progress and change for the organization. With new leadership and a renewed focus, we are laying the foundation for building a leading oncology biopharmaceutical company and realizing the value of our lead clinical candidate, ganetespib, and our proprietary Hsp90 inhibitor Drug Conjugate program,” said Anne Whitaker, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
